BBS4 Antibodies

Santa Cruz Biotechnology offers a broad range of BBS4 monoclonal antibodies for research in understanding Bardet-Biedl Syndrome and its associated pathways. BBS4 monoclonal antibodies are validated for western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), flow cytometry (FCM), and enzyme-linked immunosorbent assay (ELISA). BBS4, encoded by the BBS4 gene, plays a critical role in ciliary function and is implicated in the pathogenesis of Bardet-Biedl Syndrome, a genetic disorder characterized by obesity, retinal degeneration, and polydactyly. Understanding BBS4 function is essential for elucidating the molecular mechanisms underlying this syndrome and developing potential therapeutic strategies. BBS4 monoclonal antibodies enable precise detection and analysis of protein expression patterns in various cellular compartments. Researchers can investigate BBS4's role in ciliary transport and its interactions with other proteins involved in the BBSome complex. Advanced imaging techniques combined with BBS4 monoclonal antibodies allow visualization of protein localization and trafficking within cells. The specificity and reliability of Santa Cruz Biotechnology monoclonal antibodies support researchers worldwide in advancing our understanding of Bardet-Biedl Syndrome and related disorders.